Craig Ellis

Dan Moore

Daniel Moore

David Silver

- Roche's investigational drug combination of **giredestrant plus everolimus** demonstrated a significant improvement in **progression-free survival (PFS)** for patients with ER-positive, HER2-negative advanced breast cancer who had previously been treated with CDK4/6 inhibitors.  **[84748_f4ef97d5713941e1a9ac11680bd20e15]** 
- The **evERA Breast Cancer study** met its co-primary endpoints, making it the **first positive head-to-head trial** of an all-oral selective estrogen receptor degrader (SERD) regimen versus standard endocrine therapy.  **[84748_f4ef97d5713941e1a9ac11680bd20e15]** 
- While overall survival data are still immature, a **positive trend** favoring the giredestrant arm was observed, and the safety profiles were consistent with known effects without new concerns.  **[84748_f4ef97d5713941e1a9ac11680bd20e15]** 
- Following the announcement of these positive late-stage clinical trial results, **Roche's stock price increased by 1.5%** on the SIX Swiss Exchange.  **[84748_f4ef97d5713941e1a9ac11680bd20e15]**

Roche's Giredestrant Plus Everolimus Shows Positive Phase 3 Trial Results

- **Roche (ROG)** announced the integration of its **Accu-Chek SmartGuide** continuous glucose monitoring (CGM) solution with the **mySugr diabetes management app**, which has received **CE mark approval**.  **[84748_20250916SF73506:0]** 
- The **AI-enabled Accu-Chek SmartGuide** is the first CGM system to predict glucose levels up to **two hours ahead** and **seven hours overnight**, empowering proactive diabetes management.  **[84748_20250916SF73506:0]** 
- The solution is currently available in **13 countries** and is planned to expand to over **30 countries** across Europe, Latin America, and Asia-Pacific by year-end **2025**.  **[84748_20250916SF73506:0]** **[84748_20250916SF73506:1]** 
- Real-world evidence from the Accu-Chek SmartGuide rollout showed that using Night Low Predict reduced the likelihood of Level 1 hypoglycaemic events by **20%** and Level 2 hypoglycaemia by **31%** overnight.  **[84748_20250916SF73506:1]**

ROGERS (ROG)